Scienture Holdings (SCNX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 Oct, 2026Opening remarks and agenda
Virtual meeting called to order; Louis Kern served as secretary and Emily White as inspector of election.
Quorum confirmed with at least one-third of voting shares represented by webcast attendance or proxy.
Four matters scheduled for a vote: director elections, auditor ratification, advisory executive compensation, and conditional adjournment.
Proxy statement was available on the meeting webpage; stockholders could vote or change prior votes online.
Board and executive committee updates
Mayur Doshi, Donald G. Fell, Shankar Hariharan, Subbarao Jayanthi, and Narasimhan Mani were duly elected as directors by plurality vote.
Shareholder proposals
Proposal 1 sought election of five director nominees; nominees with the most votes for would be elected.
Proposal 2 sought ratification of CM3 Advisory as independent auditor for the FY ending December 31, 2026.
Proposal 3 sought non-binding advisory approval of named executive officer compensation as described in the proxy statement.
Proposal 4 sought authority to adjourn, if necessary and appropriate, to solicit proxies if votes or quorum were insufficient.
Latest events from Scienture Holdings
- Two new therapies launched in 2026 drive revenue growth, with a strong pipeline and expanding coverage.SCNX
H.C. Wainwright 28th Annual Global Investment Conference - Annual meeting to vote on directors, auditor, executive pay, and governance matters.SCNX
Proxy filing - Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipeline.SCNX
Corporate presentation - 2026 meeting covers director elections, auditor ratification, and executive pay, with strong governance.SCNX
Proxy filing - Q2 2026 revenue surged 510% on ARBLI™ sales, with net loss narrowing and strong liquidity maintained.SCNX
Q2 2026 - Two FDA-approved launches and a robust pipeline drive revenue growth and near-term profitability.SCNX
WTR Insights Conference: Powered by The Small Cap Showcase - Revenue fell sharply in Q3 2024 as the company shifted focus to pharma R&D and paid large dividends.SCNX
Q3 2024 - Specialty pharma pivot with high R&D spend, ongoing losses, and up to $50M ELOC funding planned.SCNX
Registration filing - Biopharma pivots to CNS/CVS drugs, seeks $50M equity, faces losses, dilution, and regulatory risk.SCNX
Registration filing